Biliary reflux as a causal factor in hypopharyngeal carcinoma: New clinical evidence and implications
Sasaki CT, Doukas SG, Costa J, Vageli DP. Biliary reflux as a causal factor in hypopharyngeal carcinoma: New clinical evidence and implications. Cancer 2019, 125: 3554-3565. PMID: 31310330, DOI: 10.1002/cncr.32369.Peer-Reviewed Original ResearchConceptsHuman hypopharyngeal squamous cell carcinomaAdjacent normal tissuesIL-6Reflux diseaseHypopharyngeal squamous cell carcinomaMiR-375Respective adjacent normal tissuesMiR-21Pilot studyEsophageal reflux diseaseIndependent risk factorNew clinical evidenceSquamous cell carcinomaOncomiR miR-21NF-κB activationMiR-21/miRTumor suppressor miR-375Quantitative polymerase chain reactionMessenger RNABiliary refluxHypopharyngeal carcinogenesisControl patientsLaryngopharyngeal refluxClinical evidenceHypopharyngeal carcinomaTemporal characteristics of NF-κB inhibition in blocking bile-induced oncogenic molecular events in hypopharyngeal cells
Doukas PG, Vageli DP, Doukas SG, Sasaki CT. Temporal characteristics of NF-κB inhibition in blocking bile-induced oncogenic molecular events in hypopharyngeal cells. Oncotarget 2019, 10: 3339-3351. PMID: 31164956, PMCID: PMC6534360, DOI: 10.18632/oncotarget.26917.Peer-Reviewed Original ResearchAcidic bileNF-κB inhibitorBAY 11Hypopharyngeal cellsIL-6MiR-155MiR-375Specific NF-κB inhibitorMiR-21NF-κB inhibitionPre-neoplastic eventsEsophageal refluxLaryngopharyngeal cancerRisk factorsMolecular eventsEarly neoplasiaTherapeutic implicationsMiR-192MiR-451aClinical useWestern blotB activationBileOncogenic factorB inhibitor